Fluence Supporting Premium Dutch Floriculture Brands to Future-Proof and Increase Sustainability
9.2.2023 16:30:00 EET | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for floriculture, medicinal cannabis and food production, is supporting sustainability and operational cost efficiency amid volatile energy market conditions in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230209005211/en/
Orchids under Fluence LED lighting at Bernhard Kwekerijen, a rose, orchid and patio plant nursery. (Photo: Business Wire)
Europe’s soaring energy prices have affected many growers in countries like the Netherlands that primarily produce electricity via the gas-powered cogeneration method. Gas prices have historically balanced between €15 and €20 per megawatt-hour (MWh) but peaked at over €300 per MWh in 2022 because of volatility due to supply, storage and weather conditions. Current energy prices have dropped to €60 per MWh, remaining roughly three times higher than what many growers planned to pay for electricity.
Leading floriculture companies dedicated to delivering high-quality products to customers—including Bernhard Kwekerijen, Moerman Lilium, Deliflor Chrysanten, Beyond Chrysant and Ten Have Plant—have made the switch from high-pressure sodium (HPS) fixtures to Fluence's LED technology, which increase photon output and energy efficiency.
“As they confront the unpredictability of Europe’s energy market, Dutch cultivators are increasingly focused on future-proofing their cultivation strategies by decreasing their dependency on fossil energy and engaging in sustainable practices,” said Gert-Jan Goes, horticulture specialist at Fluence. “Fluence’s RAPTR light fixture and Wireless Flex Dimming control panel help growers maximize their return on investment while increasing control over light intensity while increasing control over light intensity and dimming up and down creates maximum flexibility to profit from highly fluctuating energy markets.”
Moerman Lilium, a lily cultivator, has 13 hectares of crops under full LED lighting and uses Fluence’s RAPTR fixtures regulated via a Wireless Flex Dimming controller. The company—which monitors European energy prices very closely—uses Fluence solutions to react quickly and modify light intensity based on market conditions. Moerman Lilium expects to save at least 45% on electricity costs with the investment in Fluence’s LED lighting solutions.
“LED lighting allows us to be more energy efficient while adjusting our electricity use based on fluctuations in energy prices,” said Jan Moerman, co-owner of Moerman Lilium. “Switching to Fluence LEDs has saved us money and given us more flexibility in a constantly changing energy market.”
Deliflor Chrysanten is the global market leader in breeding and propagating chrysanthemum varieties. The company was in search of a high-efficiency lighting solution featuring additional green light in the spectrum for better visibility and growth. Deliflor Chrysanten opted for Fluence’s RAPTR Broad R8 spectrum in their recently renewed breeding facilities to guarantee the best circumstances for their newest varieties. The first flower trial grown under the Fluence’s fixtures turned out very successful last January. Beyond Chrysant, a leading Dutch chrysanthemum cultivator, also chose Fluence’s RAPTR solution for its customizability and high-visibility spectrum that create increased efficiency in its integrated crop management practices. Installing Fluence’s LED technology has allowed Beyond Chrysant to gain greater control over the oscillating European energy market. The company was recently named a finalist for Stichting Tuinbouw Ondernemersprijs’ “2023 Horticultural Entrepreneur Award.”
Even in hybrid lighting environments, growers are seeing the benefits of using LED technology. Bernhard Kwekerijen—a rose, orchid and patio plant nursery—promotes a carbon-neutral and sustainable operation by using geothermal heat and its own photovoltaic field of solar panels to generate energy. By incorporating Fluence’s RAPTR fixtures alongside legacy HPS solutions and maximizing light control with Wireless Flex Dimming, Bernhard Kwekerijen has elevated CO2-neutral cropping in its Phalaenopsis cultivation.
“Fluence’s technology stands out because it affords the greatest flexibility in modifying energy consumption and light intensity according to energy market price instability,” said Dennis Raadschelders, strategic account manager for commercial agriculture at Fluence. “Our Dutch floriculture growers have harnessed control over operational expenses without sacrificing product quality by emitting more light when energy prices are low, and quickly reducing light when energy prices rise.”
Fluence’s team of horticultural experts work closely alongside partners to design lighting programs based on operations-specific crop and sustainability goals. Ten Have Plant, one of the oldest potted plant nurseries in Westland, selected Fluence as its lighting solutions partner to achieve better crop and root development in addition to reducing costs and increasing energy efficiency. Ten Have Plant worked with Fluence’s horticulture team to design a lighting plan to produce cyclamen for half the year and campanula in the other half, selecting VYPR 3p Broad R6 top lights to gain control over seasonal light conditions and electricity consumption year-round.
“Fluence LED fixtures are widely used by leading cannabis, commercial agriculture and floriculture companies across Europe, demonstrating the flexibility and universal benefit in transitioning to LED technology,” said David Cohen, CEO of Fluence. “We are excited to work with Dutch floriculture growers who have deep roots in the industry and support their management of environmental conditions, sustainable operations and the highest quality crops.”
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230209005211/en/
Contact information
For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 160 93335045
For North America,
Callie Neatherlin
callie@redfancommunications.com
512-439-9720
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
